Zoetis Inc. (ZTS)

Right now is not a good time in the healthcare sector. Various companies across the space are well below highs while the broader stock market chugs along at all-time highs.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ...

Ah, 10 years ago. It was 2015, and selfie sticks and hoverboards were all over.

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two companies is the best option for those ...

It can be tempting to try to predict market movements so you buy low and sell high, but it's notoriously difficult to execute successfully. Even if you succeed once or twice, replicating that often en...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Zoetis Inc. (NYSE:ZTS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor Relations Wetteny N.

Animal health firm Zoetis Inc.  ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.